Coya Therapeutics (COYA) Investor presentation summary

Investment highlights and market opportunity

• Focus on ALS, FTD, and Alzheimer's, all with high unmet medical need and significant market potential exceeding $10B combined.

• COYA 302 and COYA 303 are novel combination therapies targeting Treg dysfunction, with ongoing and planned Phase 2 studies.

• Strategic partnerships include Dr. Reddy's, with up to $700M in milestones and a $10M investment, and ADDF supporting FTD trials.

• Estimated cash runway of $50.7M into 2H 2027.

Scientific rationale and therapeutic approach

• Combination therapies using low-dose IL-2 and CTLA4-Ig (COYA 302) or GLP-1 RA (COYA 303) aim to restore Treg function and immune balance.

• Treg dysfunction is linked to neuroinflammation and neurodegeneration; enhancing Tregs may slow or halt disease progression.

• Nobel Prize-recognized science underpins the approach, with external validation and early clinical signals in ALS and FTD.

Clinical development and data

• COYA 302 in ALS: Phase 2 ALSTARS study is enrolling, with top-line data expected 1Q 2027; prior IIT showed stabilization or improvement in ALSFRS-R scores over 48 weeks.

• COYA 302 in FTD: Phase 2a to start 2H 2026; IIT showed increased Treg function and cognitive stability over 22 weeks.

• COYA 303 in Alzheimer's: Preclinical models show reduced neuroinflammation and enhanced Treg function; clinical path to be evaluated mid-2026.